Demonstrate Durable Responses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Demonstrate Durable Responses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Demonstrate Durable Responses Today - Breaking & Trending Today

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Published: December 23, 2023

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Source: onclive.com

Related Topics:

San DiegoUnited StatesElizabeth BuddeDemonstrate Durable ResponsesRefractory Follicular LymphomaYear Follow UpPivotal PhasePartnership WithIndependent Review CommitteeFollicular LymphomaRelapsed Refractory Follicular LymphomaBispecific AntibodyBispecifict Cell EngagerPivotal Phase Ii Study

Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years

Published: December 20, 2023

Bispecific antibody also shows high response rates in frontline setting

Source: medpagetoday.com

Related Topics:

United StatesOhio State UniversityMosunetuzumab LunsumioKamij MaddocksYazeedy SawalhaGreg LaubKami MaddocksYazeed SawalhaOhio State University Wexner Medical CenterAmerican Society Of HematologyOhio State University James Comprehensive Cancer CenterAmerican SocietyMedpage TodayIm Yazeed SawalhaIm David BondOhio StateDemonstrate Durable ResponsesRefractory Follicular LymphomaYear Follow UpPivotal PhaseSubcutaneous Mosunetuzumab As First Line TherapyHigh Tumor Burden Follicular LymphomaFirst ResultsMulticenter PhaseSenior Director